Who We Are

Our history

DefiniGEN are a University of Cambridge supported company whose mission is to provide optimized human cell products to the scientific community. Human induced pluripotent stem cell (hiPSC) production was first demonstrated in 2007 and has aroused great scientific, social and economic interest earning Shiyna Yamanaka the Nobel Prize in 2012.

Our Mission

DefiniGEN’s mission is to develop, produce and commercialize highly-predictive human cell disease models to improve the safety and efficacy process of testing drugs which will help accelerate research during the candidate drug selection process, improve attrition and ultimately reduce costs.

Our Technology

OptiDIFF our proprietary core technology is a world-leading production platform developed at the University of Cambridge for the generation of iPS cells, and their differentiation into commercially prioritized cell types, including liver, pancreas and intestinal cells.